Beam Therapeutics Inc (BEAM) PT Raised to $57 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts BEAM Hot Sheet
Price: $25.87 -4.99%
Rating Summary:
20 Buy, 7 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Rating Summary:
20 Buy, 7 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Join SI Premium – FREE
Wedbush analyst David Nierengarten raised the price target on Beam Therapeutics Inc (NASDAQ: BEAM) to $57.00 (from $48.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Goldman Sachs upgrades Sirius XM Radio to Buy with $37 target
- US Lime and Minerals (USLM) PT Lowered to $131 at Freedom Broker
- Newell Brands Inc (NWL) PT Raised to $5.75 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
